Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. White (Rochester, United States of America), E. Grünig (Heidelberg, Germany), C. Jerjes-Sanchez D (Monterrey, Mexico), G. Bohns Meyer (Porto Alegre, Brazil), T. Pulido (Mexico City, Mexico), P. Sepulveda (Santiago, Chile), K. Wang (Taichung, Taiwan), C. Deng (Research Triangle Park, United States of America), R. Grover (Research Triangle Park, United States of America), D. Solum (Research Triangle Park, United States of America), A. Ousmanou (Research Triangle Park, United States of America), V. Tapson (Los Angeles, United States of America). Dose-response relationship of oral treprostinil for secondary endpoints in the FREEDOM-EV study. 5462

Member's Comments

No comment yet.

Related content which might interest you: Meta-analysis on dose-response relationship of inhaled steroids must be done in homogenous asthma populations Source: Eur Respir J 2004; 24: 513 Year: 2004 Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301 Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis Source: Eur Respir J 2004; 23: 552-558 Year: 2004 Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Will a cumulative dose reversibility test increase the power in a dose-response study comparing formoterol and terbutaline? Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007 Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4rα 2-MOE GAPMER oligonucleotide Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 A comparative study on systemic pharmacodynamic effects of two HFA formulations of salmeterol xinafoate, in healthy subjects Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008 Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology Source: Eur Respir J 2001; 17: 157-158 Year: 2001 Long-term outcome with subcutaneous treprostinil sodium in pulmonary hypertension: a 10-year single-centre study Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Multiple-dose study of AMG 317 in adults with asthma: pharmacokinetics and safety Source: Annual Congress 2008 - New treatments for asthma Year: 2008 Pharmacokinetic (PK) and pharmacodynamic (PD) data for inhaled and intranasal corticosteroids (CS) reassessed using a physiological PK/PD model Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001 Pharmacokinetic differences between inhaled treprostinil and inhaled iloprost in severe pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Dose-ranging study to assess the efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Fevipiprant (QAW039) demonstrates safety, tolerability and consistent PK at high oral doses Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Indacaterol, a novel β2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005